Brands
Van Heusen welcomes Taapsee Pannu as a new face for women’s fashion
Mumbai: Van Heusen proudly announces its new partnership with acclaimed actress Taapsee Pannu as the brand ambassador for its women’s fashion segment. This association aligns with Van Heusen’s commitment to empowering the modern woman through versatile and functional fashion.
Van Heusen celebrates the “Lead Every Role” campaign, showcasing its dynamic and trendsetting product portfolio. From formals to casuals, travel, and evening wear, Van Heusen designs its collections to resonate with ambitious and confident women. Taapsee Pannu, known for her impactful roles on and off-screen, embodies this vision of the modern Indian woman.
Commenting on the collaboration, Van Heusen’s chief operating officer, Abhay Bahugune said, “We are committed to being the force multiplier for modern, discerning women. We are excited to have Taapsee on board as she truly represents the ambitious and relentless woman of today. Taapsee is a seamless fit for Van Heusen as she has a confident personality and a strong personal mission, much like many of Van Heusen’s women customers. This is a great leap for the brand to be able to live up to the mantle of being India’s leading western wear brand for women.”
Taapsee Pannu shared her excitement, saying, “I’m extremely happy and thrilled to be the new face of Van Heusen because I feel this brand truly represents today’s modern Indian woman who is ambitious and self-made. Van Heusen has versatile and fashionable offerings, and I am super glad to be part of the Lead Every Role campaign, as this concept is extremely close to my heart.”
Van Heusen continues to expand its presence, offering its stylish collections through 150 stores across India, major department stores like Lifestyle, Shoppers Stop and Pantaloons, and on leading e-commerce platforms such as Amazon, Myntra, and its exclusive website and app.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
